-
Alebund Pharmaceuticals Completes Series C Financing to Advance Kidney Disease Pipelines
•
Shanghai-based Alebund Pharmaceuticals has announced the completion of a Series C financing round, raising RMB 550 million (USD 75.04 million). The round was led by Yangzhou Guojin Investment Group Co. Ltd and Kingray Capital, both renowned healthcare funds. The proceeds will be used to enhance the development and commercialization of…
-
GSK’s Nucala Receives New Indication Approval in China for CRSwNP
•
UK-based pharmaceutical company GlaxoSmithKline’s (GSK; NYSE: GSK) has announced that it has received another indication approval in China for its anti-interleukin-15 (IL-15) biologic, Nucala (mepolizumab). The drug is now approved as an add-on therapy with intranasal corticosteroids for the treatment of adult patients with chronic rhinosinusitis with nasal polyps (CRSwNP)…
-
Kexing Pharmaceutical Partners with Shandong Boan for Biosimilar Commercialization in Hong Kong and Macau
•
China-based Kexing Pharmaceutical (SHA: 688136) has entered into a commercialization cooperation agreement with fellow Chinese firm Shandong Boan Biotechnology Co., Ltd (HKG: 6955). The partnership aims to promote the marketing and sales of Shandong Boan’s biosimilars BA6101 and BA1102 in Hong Kong and Macau. BA6101 is a biosimilar version of…
-
Shengwei Kunteng Raises RMB 200 Million in Series A Financing for POCT Development
•
China-based Hunan Shengwei Kunteng Biotechnology Co., Ltd has announced that it has raised close to RMB 200 million (USD 27.3 million) in a Series A financing round led by Sansure, Sanway Spring, and Voyagers Capital. The funds will be directed towards research and development and the construction of an industrialization…
-
Hangzhou Highlightll Pharma Completes Pre-Series C Financing Round
•
China-based Hangzhou Highlightll Pharmaceutical Co., Ltd has announced the successful completion of a Pre-Series C financing round, raising RMB 150 million (USD 20.5 million). The investment was led by Huajin Capital, Bayland Capital, Infinity Capital, and returning investor Hankang Capital. The funds will be used to enhance the clinical development…
-
Aosaikang’s Generic Livtencity Accepted for Review by China’s NMPA
•
China’s Beijing Aosaikang Pharmaceutical Co., Ltd (SHE: 002755) has revealed that a market filing for its generic version of Japan-based Takeda’s (TYO: 4502) Livtencity (maribavir) has been accepted for review by the National Medical Products Administration (NMPA). This marks a significant step in the potential introduction of a more accessible…
-
Sinobioway Medicine Partners with Happy Life Tech for Clinical Trial Services
•
China-based Contract Manufacturing Organization (CMO) Sinobioway Medicine (SHE: 002581) has announced a clinical trial technical service agreement with compatriot firm Happy Life Tech (HLT), an affiliate of Yidu Tech (HKG: 2158). The agreement focuses on recombinant human nerve growth factor eye drops, targeting moderate to severe dry eye conditions. Phase…
-
Balance Medtech’s Interventional Pulmonary Valve Receives Fast-Track Designation from NMPA
•
China’s Beijing Balance Medical Technology Co., Ltd. (SHA: 688198) has announced that it has received fast-track designation from the Center for Medical Device Evaluation, NMPA, for its in-house developed all-comer interventional pulmonary valve and delivery system. This marks the third interventional valve product from Balance Medtech to receive fast-track status…
-
MicuRx Pharmaceuticals’ MRX-5 Receives NMPA Approval for NTM Infections Clinical Study
•
Sino-US firm MicuRx Pharmaceuticals Inc. (SHA: 688373) has announced that it has received approval from the National Medical Products Administration (NMPA) to conduct a clinical study for its drug MRX-5. The study will focus on infections caused by non-tuberculous Mycobacteria (NTM) that are sensitive to this product. MRX-5: A Promising…
-
Huahai Pharmaceutical’s HB0028 and HB002.1T Cleared for Clinical Study by NMPA
•
China-based Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521) has announced that it has received clearance from the National Medical Products Administration (NMPA) for its investigational drugs HB0028 and HB002.1T. The drugs are set to enter clinical studies, either in combination with or without standard chemotherapy, for the treatment of advanced…
-
Hengrui Pharmaceuticals Receives NMPA Approval for HRS-6768 Clinical Trial
•
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for its investigational drug HRS-6768. This approval allows the company to proceed with testing the drug in patients with advanced solid tumors. Innovative Radiation Therapy for…
-
Milestone Biotechnologies Secures Nearly 100 Million Yuan in Series A+ Funding
•
Milestone Biotechnologies, a leading biotechnology company based in Shanghai, has announced the completion of a nearly 100 million yuan Series A+ funding round. The round was led by Xingzheng Capital, with participation from Ji Gao Financial Company and Nanjing Innovation Investment Group. Kaideng Capital continued to serve as the exclusive…
-
AstraZeneca’s Tagrisso Receives NMPA Approval for EGFR-Mutated NSCLC Treatment
•
UK-based AstraZeneca (AZ, NASDAQ: AZN) has announced that it has received a new indication approval from China’s National Medical Products Administration (NMPA) for its non-small cell lung cancer (NSCLC) treatment, Tagrisso (osimertinib). This approval is for the use of Tagrisso in treating adult patients with locally advanced, unresectable NSCLC, whose…
-
NMPA Approves Lynparza as Adjuvant Treatment for High-Risk Breast Cancer Patients
•
The National Medical Products Administration (NMPA) in China has granted AstraZeneca (AZ, NASDAQ: AZN) and Merck, Sharp & Dohme (MSD; NYSE: MRK) a regulatory nod for their drug Lynparza (olaparib). The approval is for adjuvant treatment in adult patients with early high-risk breast cancer who have undergone neoadjuvant or adjuvant…
-
Gilead Sciences’ Sunlenca Receives NMPA Approval for Multidrug-Resistant HIV-1 Infection
•
US-based pharmaceutical company Gilead Sciences Inc., (NASDAQ: GILD), has announced that it has received marketing approval from China’s National Medical Products Administration (NMPA) for its drug Sunlenca (lenacapavir). The drug is approved for use in combination with antiretroviral drugs for adult patients with multidrug-resistant human immunodeficiency virus type 1 (HIV-1)…
-
WinHealth Pharma’s Difelikefalin Receives NMPA Review for Market Approval
•
China-based Hong Kong WinHealth Pharma Group has announced that the National Medical Products Administration (NMPA) has accepted its market approval filing for review for difelikefalin. WinHealth holds exclusive development and commercialization rights to the Category 5.1 drug in China, following a licensing deal secured with Vifor Fresenius Medical Care Renal…
-
Thederma’s TAN-118 Receives Tacit Clinical Approval from China’s CDE for Global Trials
•
Shanghai-based Thederma has announced that its drug candidate TAN-118 has obtained tacit clinical approval from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) in China. This follows the clearance received from the US FDA in October of the previous year, indicating that TAN-118, an AhR…
-
Shenzhen Hepalink Pharmaceuticals to Distribute Gabapentin in US under New Agreement
•
China-based Shenzhen Hepalink Pharmaceutical Group Co., Ltd (SHE: 002399, HKG: 9989) has announced a product distribution agreement with Zhejiang Yongtai Technology Co., Ltd. The agreement, for which no financial details have been disclosed, appoints Hepalink as the entity responsible for the marketing, promotion, and commercialization of Yongtai’s gabapentin in the…
-
Innovent Biologics’ Taletrectinib Gains NMPA Approval for ROS1 Positive NSCLC
•
China-based Innovent Biologics, Inc. (HKG: 1801) has announced receiving an additional marketing approval from the National Medical Products Administration (NMPA) for its drug taletrectinib. This second-generation ROS1 tyrosine kinase inhibitor is now approved for use in treating adult patients with ROS1 positive locally advanced or metastatic non-small cell lung cancer…
-
MabPharm’s CMAB807 Biosimilar Infliximab Approved in Pakistan
•
Taizhou-based monoclonal antibody (mAb) biosimilar specialist MabPharm Ltd (HKG: 2181) has announced the receipt of market approval for CMAB807, a biosimilar version of Johnson & Johnson (J&J, NYSE: JNJ)’s Remicade (infliximab), in Pakistan. This follows similar approvals in Peru and Indonesia last year. The approval encompasses all six indications, which…
